13 completed, 4 unknown, 2 terminated, 1 active not recruiting. 10 Phase 2, 8 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Unknown 2, Terminated 1 |
| Phase 1 | 8 | Completed 5, Active not recruiting 1, Terminated 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Recurrent Glioblastoma Multiforme: new trials by email Literature Review of Recurrent Glioblastoma Multiforme trials Research Report on Recurrent Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Berubicin Hydrochloride - Recurrent Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | WPD Pharmaceuticals Sp. z o.o. | 5 | 2022-12-07 | 2024-06-06 |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma SNC-109 CAR-T Cells - Recurrent Glioblastoma Multiforme | Phase 1 | Unknown | Shanghai Simnova Biotechnology Co.,Ltd. | 16 | 2022-06-24 | 2024-02-23 |
| A Prospective, Open-label, Single-arm Clinical Study TTFields - Recurrent Glioblastoma Multiforme | Not applicable | Unknown | Sun Yat-sen University | 40 | 2020-04-01 | 2020-12-30 |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Radiation Therapy, AZD1390 - Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme | Phase 1 | Completed | AstraZeneca | 159 | 2018-04-02 | 2026-10-15 |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme buparlisib, carboplatin, lomustine - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Novartis Pharmaceuticals | 35 | 2014-02-28 | 2020-12-09 |
| Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma M032 (NSC 733972) - Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme | Phase 1 | Active not recruiting | University of Alabama at Birmingham | 29 | 2013-11-25 | 2025-10-02 |
| Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Vorinostat, Bevacizumab - Recurrent Glioblastoma Multiforme, Malignant Glioma | Phase 2 | Completed | Duke University | 48 | 2013-01-01 | 2017-03-06 |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients NovoTTF-100A - Recurrent Glioblastoma Multiforme | Phase 4 | Terminated | NovoCure Ltd. | 13 | 2012-12-01 | 2016-03-02 |
| Procarbazine and Lomustine in Recurrent Glioblastoma lomustine and procarbazine - Recurrent Glioblastoma Multiforme | Phase 2 | Unknown | Incheon St.Mary's Hospital | 52 | 2012-10-01 | 2012-12-03 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors LDE225, BKM120 - Dose Escalation, Safety | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2012-07-01 | 2020-12-19 |
| Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Stereotactic hypofractionated RT 5x5Gy, Stereotactic hypofractionated RT 5x7Gy - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Andre Tsin Chih Chen | 40 | 2011-10-01 | 2024-12-09 |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme temozolomide and bevacizumab - Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | Phase 2 | Completed | Center for Neurosciences, Tucson | 30 | 2009-04-01 | 2017-03-30 |
| Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors AutoLITT system - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | Monteris Medical | 10 | 2008-08-01 | 2021-08-24 |
| CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan CT-322, irinotecan hydrochloride - Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | Phase 2 | Unknown | Adnexus, A Bristol-Myers Squibb R&D Company | 72 | 2007-10-01 | 2010-10-27 |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Sorafenib and Temozolomide - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Duke University | 32 | 2007-09-01 | 2013-06-24 |
| Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Panzem NCD, Temozolomide - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 15 | 2007-04-01 | 2008-11-25 |
| Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme 131-I-chTNT-1/B MAB - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Peregrine Pharmaceuticals | 12 | 2006-11-01 | 2011-08-05 |
| Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) NovoTTF-100A - Recurrent Glioblastoma Multiforme | Phase 3 | Completed | NovoCure Ltd. | 236 | 2006-09-01 | 2012-05-01 |
| Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Panzem Nanocrystal Colloidal Dispersion - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 27 | 2006-01-01 | 2008-12-10 |
| Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors TP-38, TP38 - Recurrent Glioblastoma Multiforme | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 56 | 2003-10-01 | 2012-01-20 |
Glioblastoma (20) · Brain Neoplasms (9) · Glioma (5) · Gliosarcoma (3) · Recurrence (3) · Astrocytoma (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Inhibition, Psychological (1) · Meningeal Neoplasms (1) · Stomach Neoplasms (1) · Virus Diseases (1)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Glandular and Epithelial (20) · Neoplasms, Nerve Tissue (20) · Neoplasms, Neuroepithelial (20) · Neuroectodermal Tumors (20) · Astrocytoma (19) · Glioma (15) · Neoplasms by Site (11) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Brain Diseases (9) · Central Nervous System Diseases (9) · Central Nervous System Neoplasms (9)
Temozolomide (3) · 2-Methoxyestradiol (2) · Bevacizumab (2) · Lomustine (2) · NVP-BKM120 (2) · 131I-chimeric TNT-1-B monoclonal antibody (1) · AZD1390 (1) · CT-322 (1) · Carboplatin (1) · Immunotoxins (1) · Irinotecan (1) · Procarbazine (1) · Radiotherapy (1) · Sorafenib (1) · Vorinostat (1)
CASI pharmaceuticals, Inc. (2) · Duke University (2) · Novartis Pharmaceuticals (2) · NovoCure Ltd. (2) · Adnexus, A Bristol-Myers Squibb R&D Company (1) · Andre Tsin Chih Chen (1) · AstraZeneca (1) · Center for Neurosciences, Tucson (1) · Incheon St.Mary's Hospital (1) · Monteris Medical (1) · Peregrine Pharmaceuticals (1) · Shanghai Simnova Biotechnology Co.,Ltd. (1) · Sun Yat-sen University (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · University of Alabama at Birmingham (1)
United States (14) · Australia (2) · Belgium (2) · Canada (2) · China (2) · France (2) · Germany (2) · Spain (2) · United Kingdom (2) · Austria (1) · Brazil (1) · Czechia (1) · Israel (1) · Italy (1) · Japan (1)
Andre T Chen, M.D. / PhD (1) · Andrew E Sloan, MD, FACS (1) · Andrew Sloan, MD (1) · Annick Desjardins, MD (1) · Anthony Chalmers (1) · Brandon Imber (1) · David A Reardon, MD (1) · David A. Reardon, M.D. (1) · Deborah Forst (1) · Don-Sup Chung, MD (1) · Gene Barnett, MD (1) · Herbert Engelhard, MD, PhD (1) · James M. Markert, MD (1) · Jan Drappatz (1) · Katherine Peters, MD, PhD (1)
PMID 20443129, PMID 22608262, PMID 23560574, PMID 29133513, PMID 32665311, PMID 36239858, PMID 38232937
2017 (1), R01CA217179 (1)